ArticlePharmacoEconomics2025

When Evidence Falls Short-Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal.

Isaac Corro Ramos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.